Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Non-Hodgkin’s Lymphoma (887)

Hodgkin Lymphoma (59)

Non-Hodgkin’s Lymphoma (887)

Hodgkin Lymphoma (59)

›

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 4 days (New A1) pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 4d	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 4 days pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 4 days - (New A1)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: A1 - Approval NCCN - 6 days (New A2) mosunetuzumab Sensitive : A1 NCCN - 6d	mosunetuzumab Sensitive: A1 - Approval NCCN - 6 days mosunetuzumab Sensitive : A1 NCCN - 6 days - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline NCCN - 6 days (New A2) acalabrutinib Sensitive : A2 NCCN - 6d	acalabrutinib Sensitive: A2 - Guideline NCCN - 6 days acalabrutinib Sensitive : A2 NCCN - 6 days - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline NCCN - 6 days (New A2) tazemetostat Sensitive : A2 NCCN - 6d	tazemetostat Sensitive: A2 - Guideline NCCN - 6 days tazemetostat Sensitive : A2 NCCN - 6 days - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) Bv-AVE-PC Sensitive : A2 NCCN - 2wk	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 2 weeks Bv-AVE-PC Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) AEPA-CAPDAC Sensitive : A2 NCCN - 2wk	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 2 weeks AEPA-CAPDAC Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CVbP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) CVbP Sensitive : A2 NCCN - 2wk	CVbP Sensitive: A2 - Guideline NCCN - 2 weeks CVbP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) CHOP Sensitive : A2 NCCN - 2wk	CHOP Sensitive: A2 - Guideline NCCN - 2 weeks CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	OEPA Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) OEPA Sensitive : A2 NCCN - 2wk	OEPA Sensitive: A2 - Guideline NCCN - 2 weeks OEPA Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ABVE-PC Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) ABVE-PC Sensitive : A2 NCCN - 2wk	ABVE-PC Sensitive: A2 - Guideline NCCN - 2 weeks ABVE-PC Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	cisplatin Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) cisplatin Sensitive : A2 NCCN - 3wk	cisplatin Sensitive: A2 - Guideline NCCN - 3 weeks cisplatin Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	AspaMetDex Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) AspaMetDex Sensitive : A2 NCCN - 3wk	AspaMetDex Sensitive: A2 - Guideline NCCN - 3 weeks AspaMetDex Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	DDGP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) DDGP Sensitive : A2 NCCN - 3wk	DDGP Sensitive: A2 - Guideline NCCN - 3 weeks DDGP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	SMILE Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) SMILE Sensitive : A2 NCCN - 3wk	SMILE Sensitive: A2 - Guideline NCCN - 3 weeks SMILE Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks (New B) RG6026 Sensitive : B Roche Press Release - 3wk	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks RG6026 Sensitive : B Roche Press Release - 3 weeks - (New B)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Lymphoma	No biomarker	Lymphoma	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1

Lymphoma

Associations(1022)

Associations
(1022)